[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519429":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":283,"collaborators":285,"id":289,"slug":290,"hasResults":291,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":11,"eligibilityCriteria":295,"healthyVolunteers":291,"sex":296,"minAge":297,"maxAge":11,"enrollmentInfo":298,"targetDuration":11,"studyType":301,"phases":302,"briefSummary":304,"conditions":305,"keywords":11,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":316},{"fullName":5,"class":6},"Canadian Cancer Trials Group","NETWORK",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Paclitaxel and Ramucriumab","ACTIVE_COMPARATOR",null,[13,14],"Drug: Paclitaxel","Drug: Ramucirumab",{"label":16,"type":17,"description":11,"interventionNames":18},"Zanidatamab + Paclitaxel and Ramucirumab","EXPERIMENTAL",[13,14,19],"Drug: Zanidatamab",[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","Paclitaxel","80 mg\u002Fm²",[9,16],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Ramucirumab","8 mg\u002Fkg",[9,16],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"Zanidatamab","Dose and schedule to be assigned at enrollment",[16],[35],{"name":36,"affiliation":37,"role":38},"Elena Elimova","University Health Network, Princess Margaret Cancer Centre, Toronto ON Canada","STUDY_CHAIR",[40],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"Chris O'Callaghan","CONTACT","613-533-6430","cocallaghan@ctg.queensu.ca",[46,63,78,92,106,121,135,147,159,172,184,198,211,221,231,246,256,270],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Arthur J.E. Child Comprehensive Cancer Centre","RECRUITING","Calgary","Alberta","T2N 5G2","Canada","CA",{"type":55,"coordinates":56},"Point",[57,58],-114.08529,51.05011,{"lat":58,"lon":57},[61],{"name":62,"role":42,"phone":11,"phoneExt":11,"email":11},"Hatim Karachiwala",{"facility":64,"status":48,"city":65,"state":66,"zip":67,"country":52,"countryCode":53,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"BCCA - Vancouver","Vancouver","British Columbia","V5Z 4E6",{"type":55,"coordinates":69},[70,71],-123.11934,49.24966,{"lat":71,"lon":70},[74],{"name":75,"role":42,"phone":76,"phoneExt":77,"email":11},"Howard Lim","604 877-6000","672699",{"facility":79,"status":48,"city":80,"state":81,"zip":82,"country":52,"countryCode":53,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"CancerCare Manitoba","Winnipeg","Manitoba","R3E 0V9",{"type":55,"coordinates":84},[85,86],-97.14704,49.8844,{"lat":86,"lon":85},[89],{"name":90,"role":42,"phone":91,"phoneExt":11,"email":11},"James T. Paul","204 787-2108",{"facility":93,"status":48,"city":94,"state":95,"zip":96,"country":52,"countryCode":53,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"QEII Health Sciences Centre","Halifax","Nova Scotia","B3H 1V7",{"type":55,"coordinates":98},[99,100],-63.57688,44.64269,{"lat":100,"lon":99},[103],{"name":104,"role":42,"phone":105,"phoneExt":11,"email":11},"Stephanie Snow","902 473-3739",{"facility":107,"status":48,"city":108,"state":109,"zip":110,"country":52,"countryCode":53,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Royal Victoria Regional Health Centre","Barrie","Ontario","L4M 6M2",{"type":55,"coordinates":112},[113,114],-79.66634,44.40011,{"lat":114,"lon":113},[117],{"name":118,"role":42,"phone":119,"phoneExt":120,"email":11},"Dawn Ng","705 728-9090","43340",{"facility":122,"status":48,"city":123,"state":109,"zip":124,"country":52,"countryCode":53,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Juravinski Cancer Centre at Hamilton Health Sciences","Hamilton","L8V 5C2",{"type":55,"coordinates":126},[127,128],-79.84963,43.25011,{"lat":128,"lon":127},[131],{"name":132,"role":42,"phone":133,"phoneExt":134,"email":11},"Oren Levine","905 387-9495","63123",{"facility":136,"status":48,"city":137,"state":109,"zip":138,"country":52,"countryCode":53,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Kingston Health Sciences Centre","Kingston","K7L 2V7",{"type":55,"coordinates":140},[141,142],-76.48098,44.22976,{"lat":142,"lon":141},[145],{"name":146,"role":42,"phone":11,"phoneExt":11,"email":11},"Brooke Wilson",{"facility":148,"status":48,"city":149,"state":109,"zip":150,"country":52,"countryCode":53,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Waterloo Regional Health Network (WRHN)","Kitchener","N2G 1G3",{"type":55,"coordinates":152},[153,154],-80.5112,43.42537,{"lat":154,"lon":153},[157],{"name":158,"role":42,"phone":11,"phoneExt":11,"email":11},"Anupam Batra",{"facility":160,"status":48,"city":161,"state":109,"zip":162,"country":52,"countryCode":53,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"London Health Sciences Centre Research Inc.","London","N6A 5W9",{"type":55,"coordinates":164},[165,166],-81.23304,42.98339,{"lat":166,"lon":165},[169],{"name":170,"role":42,"phone":171,"phoneExt":11,"email":11},"Daniel Breadner","519 685-8600",{"facility":173,"status":48,"city":174,"state":109,"zip":175,"country":52,"countryCode":53,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Lakeridge Health Oshawa","Oshawa","L1G 2B9",{"type":55,"coordinates":177},[178,179],-78.84957,43.90012,{"lat":179,"lon":178},[182],{"name":183,"role":42,"phone":11,"phoneExt":11,"email":11},"Amin Kay",{"facility":185,"status":48,"city":186,"state":109,"zip":187,"country":52,"countryCode":53,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Ottawa Hospital Research Institute","Ottawa","K1H 8L6",{"type":55,"coordinates":189},[190,191],-75.69812,45.41117,{"lat":191,"lon":190},[194],{"name":195,"role":42,"phone":196,"phoneExt":197,"email":11},"Rachel Goodwin","613 737-8899","70185",{"facility":199,"status":48,"city":200,"state":109,"zip":201,"country":52,"countryCode":53,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"Odette Cancer Centre","Toronto","M4N 3M5",{"type":55,"coordinates":203},[204,205],-79.39864,43.70643,{"lat":205,"lon":204},[208],{"name":209,"role":42,"phone":210,"phoneExt":11,"email":11},"Michael Raphael","416 480-5000",{"facility":212,"status":48,"city":200,"state":109,"zip":213,"country":52,"countryCode":53,"cosmosGeoPoint":214,"geoPoint":216,"contacts":217},"St. Michael's Hospital","M5B 1W8",{"type":55,"coordinates":215},[204,205],{"lat":205,"lon":204},[218],{"name":219,"role":42,"phone":220,"phoneExt":11,"email":11},"Suneil Khanna","416 864-5734",{"facility":222,"status":48,"city":200,"state":109,"zip":223,"country":52,"countryCode":53,"cosmosGeoPoint":224,"geoPoint":226,"contacts":227},"University Health Network","M5G 2M9",{"type":55,"coordinates":225},[204,205],{"lat":205,"lon":204},[228],{"name":36,"role":42,"phone":229,"phoneExt":230,"email":11},"416 946-4501","2520",{"facility":232,"status":48,"city":233,"state":234,"zip":235,"country":52,"countryCode":53,"cosmosGeoPoint":236,"geoPoint":240,"contacts":241},"CHUM-Centre Hospitalier de l'Universite de Montreal","Montreal","Quebec","H2X 3E4",{"type":55,"coordinates":237},[238,239],-73.58781,45.50884,{"lat":239,"lon":238},[242],{"name":243,"role":42,"phone":244,"phoneExt":245,"email":11},"Moustapha Tehfe","514 890-8000","25381",{"facility":247,"status":48,"city":233,"state":234,"zip":248,"country":52,"countryCode":53,"cosmosGeoPoint":249,"geoPoint":251,"contacts":252},"Centre Integre Universitaire De Sante Et De Services","H4J 1C5",{"type":55,"coordinates":250},[238,239],{"lat":239,"lon":238},[253],{"name":254,"role":42,"phone":255,"phoneExt":11,"email":11},"Setareh Samimi","514 338-2150",{"facility":257,"status":48,"city":258,"state":259,"zip":260,"country":52,"countryCode":53,"cosmosGeoPoint":261,"geoPoint":265,"contacts":266},"Allan Blair Cancer Centre","Regina","Saskatchewan","S4T 7T1",{"type":55,"coordinates":262},[263,264],-104.6178,50.45008,{"lat":264,"lon":263},[267],{"name":268,"role":42,"phone":269,"phoneExt":11,"email":11},"Muhammad Salim","306 766-2691",{"facility":271,"status":48,"city":272,"state":259,"zip":273,"country":52,"countryCode":53,"cosmosGeoPoint":274,"geoPoint":278,"contacts":279},"Saskatoon Cancer Centre","Saskatoon","S7N 4H4",{"type":55,"coordinates":275},[276,277],-106.66892,52.13238,{"lat":277,"lon":276},[280],{"name":281,"role":42,"phone":282,"phoneExt":11,"email":11},"Adnan Zaidi","306 655-2710",{"type":284,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[286],{"name":287,"class":288},"Jazz Pharmaceuticals","INDUSTRY","100519429","phase-2-paclitaxel-and-ramucirumab---zanidatamab-in-her2-postive-advanced-gastroesophageal-adenocarcinoma-100519429",false,"NCT06043427","Paclitaxel and Ramucirumab +\u002F- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma","A Randomized Phase II Study of Paclitaxel and Ramucirumab +\u002F- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma","Inclusion Criteria:\n\n* Participants must have histologically or pathologically confirmed gastroesophageal adenocarcinoma (stomach, gastroesophageal junction or esophagus) that is unresectable or metastatic and which must be HER2 positive as confirmed by central testing using FDA-approved HER2 assay. HER2 positive is defined as IHC 3+, or IHC 2+ and FISH positive.\n* Participants must have received and failed at least one prior trastuzumab-containing regimen in combination with platinum-based chemotherapy for treatment of locally advanced or metastatic disease. Failure is defined as demonstrated objective disease progression (radiologic) on the most recently administered HER2 targeting agent.\n* Participants must have presence of measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1).\n* Participants must be considered a suitable candidate for, and able to receive chemotherapy for advanced disease with paclitaxel and ramucirumab.\n* Participants must consent to the provision of samples of blood, serum and plasma in order that the specific correlative marker assays may be conducted.\n* Participants must consent to provision of, and investigator(s) must confirm access to a representative formalin fixed paraffin embedded (FFPE) block of tumour tissue\u002F or a predetermined number of freshly cut slides of representative tumour tissue of adequate amount and quality in order that the central HER2 testing may be done\n* Participants must be ≥ 18 years of age.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participants must have a life expectancy of at least 12 weeks at the time of study entry\n* Imaging investigations including CT\u002FMRI of chest\u002Fabdomen\u002Fpelvis or other scans as necessary to document all sites of disease must be done within 28 days prior to randomization\n* Participants must have adequate cardiac function by ECHO or MUGA defined as EF ≥ 50%. This is to be performed within 4 weeks (preferred) but no more than 8 weeks prior to randomization\n* Participants must have adequate normal organ and marrow function\n* Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life and\u002For health utility questionnaires in either English or French\n* Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements.\n* Participant must be accessible for treatment and follow-up. Investigators must assure themselves the participants enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.\n* In accordance with CCTG policy, protocol treatment is to begin within 2 working days of participant enrollment\n* Participants of childbearing potential must have agreed to use a highly effective contraceptive method for the entire period of study treatment and for at least 7 months after discontinuing study therapy.\n\nExclusion Criteria:\n\n* Participants with a history of other malignancies except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years. Patients with a history of other malignancies detected at an early stage and whom the investigator believes have been curatively treated and are at a low risk of recurrence MAY be eligible\n* Participants receiving therapy in a concurrent clinical study. Patients must agree not to participate in other clinical studies during their participation in this trial while on study treatment\n* Participants with active or uncontrolled intercurrent illness\n* Participants with human immunodeficiency virus infection (positive HIV 1\u002F2 antibodies), active hepatitis B infection (positive HBV surface antigen (HBsAg)) or positive for hepatitis C (HCV) antibody may be considered for enrollment, if infection is adequately controlled in the opinion of the investigator.\n* Any active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy\n* Any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol\n* Any unresolved toxicity (CTCAE grade 2 or greater) from previous anti-cancer therapy which in the opinion of the investigator puts the participant at higher than expected risk during protocol treatment. However, participants with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational products in the Investigator's opinion may be included.","ALL","18 Years",{"count":299,"type":300},168,"ESTIMATED","INTERVENTIONAL",[303],"PHASE2","This study is being done to answer the following question:\n\nCan the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug called zanidatamab to the usual combination of drugs?\n\nWe are doing this study because we want to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for gastroesophageal cancer",[306],"Gastroesophageal Adenocarcinoma","2026-06-08",{"date":309,"type":310},"2026-06-09","ACTUAL",{"date":312,"type":310},"2024-04-16",{"date":314,"type":300},"2026-12-31",{"name":5,"class":6},18]